New oral anticoagulants: a practical guide for clinicians

被引：0
作者：
Ann K. Wittkowsky
机构：
[1] University of Washington School of Pharmacy,Anticoagulation Services
[2] University of Washington Medical Center,undefined
来源：
Journal of Thrombosis and Thrombolysis | 2010年 / 29卷
关键词：
Anticoagulation; Dabigatran; Rivaroxaban; Apixaban;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The search for an oral anticoagulant with acceptable efficacy and safety in the treatment and prevention of venous and arterial thromboembolism, but with practical advantages over warfarin, has been a focus of drug development for many years. Three oral agents, dabigatran, rivaroxaban, and apixaban, are nearing approval in the US. Their use in practice will be guided by the clinical trials available, as well as their pharmacokinetic and pharmacodynamic properties. Practitioners need to be fully aware of these characteristics in order to use these agents appropriately in clinical practice. This review compares the results of the phase 3 trials investigating these agents in the prevention of venous thromboembolism in patients undergoing orthopedic surgery, examines the reporting of bleeding complications in the trials, and highlights various practical considerations regarding their use in clinical practice.
引用
收藏
页码：182 / 191
页数：9
相关论文
共 73 条
  • [1] Bauer KA(2006)New anticoagulants: antiIIa vs. antiXa—is one better? J Thromb Thrombolysis 21 67-72
  • [2] Weitz JI(2007)Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 5 65-67
  • [3] Ansell J(2007)Factor Xa vs. thrombin: is factor Xa a better target? J Thromb Haemost 5 60-64
  • [4] Schulman S(2003)Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation? Semin Thromb Haemost 29 33-36
  • [5] Erikkson BI(2007)Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2178-2185
  • [6] Dahl OE(2007)Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total hip replacement: a randomized, double-blind non-inferiority trial Lancet 370 949-956
  • [7] Rosencher N(2009)Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 1-9
  • [8] Erikkson B(2008)Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 381-453
  • [9] Dahl OE(2009)Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following hip or knee arthroplasty. A meta-analysis Thromb Haemost 101 77-85
  • [10] Rosencher N(2008)Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty New Engl J Med 358 2765-2775
12345678